CereVasc

CereVasc announced a leadership change on September 15, 2026. CereVasc appointed Tony Kingsley President and CEO as Dan Levangie moved to Chairman, with Kingsley to lead strategy and operations ahead of the eShunt System’s commercial introduction.

What changed

Tony Kingsley was named President and Chief Executive Officer. Dan Levangie moved from President and CEO to Chairman of the Board and will continue providing strategic guidance and support through the company’s next phase of growth.

• Leader: Tony Kingsley
• Role: President and Chief Executive Officer
• Effective: September 15, 2026
• Announcement date: September 15, 2026

Leadership background

CereVasc said Kingsley brings extensive leadership experience and a strong track record of building and advancing innovative healthcare companies. Levangie said Kingsley has deep commercial leadership experience in neurology, a strategic perspective, and a passion for advancing healthcare innovation.

The mandate

CereVasc said Kingsley will lead its strategy and operations as the company prepares for the commercial introduction of the eShunt System, a device intended to enable the first minimally invasive treatment for communicating hydrocephalus.

Why this matters for GTM teams

Executive appointments can precede changes in strategy, operating cadence, hiring, partnerships, and technology priorities. The useful signal is not the title alone: teams should watch the new leader’s stated mandate, prior playbook, organizational scope, and the initiatives announced during the first two quarters.

Source and methodology

This leadership profile is based on the company’s announcement. Roles, transition timing, and biographical details are presented as announced; SalesTools Research does not infer undisclosed succession plans.

Primary source: CereVasc leadership announcement.